Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anixa Biosciences

2.76
-0.0800-2.82%
Post-market: 2.760.00000.00%17:30 EDT
Volume:80.92K
Turnover:226.27K
Market Cap:88.90M
PE:-7.32
High:2.87
Open:2.87
Low:2.75
Close:2.84
Loading ...

CEO Amit Kumar Reports Acquisition of Common Shares in Anixa Biosciences Inc

Reuters
·
05 Jun

Promising Developments at Anixa Biosciences: Buy Rating Reiterated with $7 Price Target

TIPRANKS
·
03 Jun

Anixa Biosciences CEO Highlights Breakthrough Breast Cancer Vaccine on NewsNation Interview

Reuters
·
03 Jun

Anixa Biosciences Completes Enrollment in Phase 1 Trial of Breast Cancer Vaccine Funded by U.S. Department of Defense

Reuters
·
02 Jun

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

THOMSON REUTERS
·
02 Jun

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
29 May

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

PR Newswire
·
30 Apr

BRIEF-Anixa Biosciences- Receives Notice Of Allowance For Car-T Technology Patent

Reuters
·
14 Apr

Anixa Biosciences Inc - Receives Notice of Allowance for CAR-T Technology Patent

THOMSON REUTERS
·
14 Apr

Anixa Biosciences Shares Rise After Notice of Patent Allowance for Breast Cancer Vaccine

MT Newswires Live
·
10 Apr

BRIEF-Anixa Biosciences Receives Notice Of Allowance From U.S. Patent And Trademark Office

Reuters
·
09 Apr

Anixa Biosciences Receives Notice of Allowance From U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

THOMSON REUTERS
·
09 Apr

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

PR Newswire
·
09 Apr

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

Benzinga
·
09 Apr

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
26 Mar

Anixa Enters Letter of Intent to Develop Verdi's AI-Guided Cancer Vaccines

MT Newswires Live
·
25 Mar

BRIEF-Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Reuters
·
25 Mar

Anixa Biosciences Enters Letter of Intent With Verdi Solutions to Develop Artificial Intelligence-Guided Personalized and off-the-Shelf Cancer Vaccines

THOMSON REUTERS
·
25 Mar

EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines

Benzinga
·
25 Mar

Anixa Biosciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Mar